Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DURECT CORPORATION

(DRRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société DURECT CORPORATION
09/23DURECT CORPORATION : Fireside Chat at the Cantor Fitzgerald Global Healthcare Conference 2..
PR
09/15DURECT CORPORATION : Fireside Chat at Oppenheimer's Fall Healthcare Life Sciences & MedTec..
PR
09/07DURECT CORPORATION : Fireside Chat at the H.C. Wainwright Annual Global Investment Confere..
PR
07/30DURECT : Management's Discussion and Analysis of Financial Condition and Results of Operat..
AQ
07/29DURECT : Q2 Earnings Snapshot
AQ
07/29DURECT CORPORATION ANNOUNCES SECOND : 30 p.m. ET (Form 8-K)
PU
07/29DURECT CORP : Results of Operations and Financial Condition, Financial Statements and Exhi..
AQ
07/29DURECT CORPORATION : Announces Second Quarter 2021 Financial Results and Update of Program..
PR
07/22DURECT CORPORATION : to Announce Second Quarter 2021 Financial Results and Provide Busines..
PR
07/14DURECT CORPORATION : to Present at the 2021 Epigenetic Therapeutic Targets Virtual Summit
PR
06/25DURECT : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Ma..
AQ
06/23DURECT CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/23DURECT : Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1..
PU
06/23DURECT CORPORATION : Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH..
PR
06/16DURECT : Certificate of Amendment to the Amended and Restated Certificate of Incorporation..
PU
06/16DURECT CORP : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission ..
AQ
06/09DURECT CORPORATION : to Present Additional Clinical Data from DUR-928 Studies in NASH (Pha..
PR
06/02DURECT : FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (Form 8-K)
PU
06/02DURECT CORP : Entry into a Material Definitive Agreement, Financial Statements and Exhibit..
AQ
05/05DURECT : Management's Discussion and Analysis of Financial Condition and Results of Operat..
AQ
05/04DURECT : Q1 Earnings Snapshot
AQ
05/04DURECT CORPORATION ANNOUNCES FIRST Q : 30 p.m. ET
PU
05/04DURECT CORP : Results of Operations and Financial Condition, Financial Statements and Exhi..
AQ
05/04DURECT CORPORATION : Announces First Quarter 2021 Financial Results and Update of Programs
PR
04/27DURECT CORPORATION : to Announce First Quarter 2021 Financial Results and Provide Business..
PR
03/09DURECT CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
03/09DURECT CORPORATION : Announces Publication of DUR-928's Mechanism of Action
PR
03/08DURECT : Results of Operations and Financial Condition, Financial Statements and Exhibits ..
AQ
03/05DURECT : Management's Discussion and Analysis of Financial Condition and Results of Operat..
AQ
03/04DURECT : Q4 Earnings Snapshot
AQ
03/04DURECT CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
03/04DURECT CORPORATION : Announces Fourth Quarter and Full Year 2020 Financial Results and Upd..
PR
03/03DURECT CORPORATION : to Participate in Three Investor Conferences in March 2021
PR
02/25DURECT CORPORATION : to Announce 2020 Financial Results and Provide Business Update on Mar..
PR
02/23DURECT CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
02/05DURECT CORP : Entry into a Material Definitive Agreement, Other Events, Financial Statemen..
AQ
02/04DURECT CORPORATION : Announces Pricing of $42.5 Million Public Offering of Common Stock
PR
02/04DURECT CORP : Results of Operations and Financial Condition, Other Events (form 8-K)
AQ
02/03DURECT CORPORATION : Announces Proposed Offering of Common Stock
PR
02/03DURECT CORPORATION : Announces U.S. FDA Approval of POSIMIR for Post-Surgical Pain Reducti..
AQ
02/02DURECT CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
02/02DURECT CORPORATION : Announces U.S. FDA Approval of POSIMIR® For Post-Surgical Pain Reduct..
PR
01/25DURECT CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/25DURECT CORPORATION : Announces First Patient Dosed in Phase 2b AHFIRM Study of DUR-928 in ..
PR
01/05DURECT CORP : Change in Directors or Principal Officers, Other Events, Financial Statement..
AQ
01/05DURECT CORPORATION : Appoints Two New Board Members
PR
01/04DURECT CORPORATION : Announces Closing of LACTEL® Absorbable Polymer Product Line Sale to ..
PR
2020DURECT CORPORATION : to Participate in Investor Conferences in January 2021
PR
2020DURECT CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2020DURECT CORPORATION : Announces DUR-928 Granted FDA Fast Track Designation for Treatment of..
PR
2020DURECT CORPORATION : to Sell its LACTEL Absorbable Polymer Product Line to Evonik for $15 ..
AQ
2020DURECT CORP : Entry into a Material Definitive Agreement, Financial Statements and Exhibit..
AQ
2020DURECT CORPORATION : to Sell its LACTEL® Absorbable Polymer Product Line to Evonik for $15..
PR
2020DURECT CORPORATION : Announces Additional Safety Data and Efficacy Signals from Phase 1b C..
AQ
2020DURECT CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2020DURECT CORPORATION : Announces Additional Safety Data and Efficacy Signals from Phase 1b C..
PR
2020DURECT CORPORATION : to Host Webinar on the Treatment of Alcoholic Hepatitis Featuring Chi..
AQ
2020DURECT : Management's Discussion and Analysis of Financial Condition and Results of Operat..
AQ
2020DURECT CORPORATION : Appoints Dr. Norman Sussman as Chief Medical Officer
AQ
2020DURECT CORPORATION : Announces Third Quarter 2020 Financial Results and Update of Programs
AQ
2020DURECT : 3Q Earnings Snapshot
AQ
2020DURECT CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2020DURECT CORP : Change in Directors or Principal Officers, Financial Statements and Exhibits..
AQ
2020DURECT CORPORATION : Announces Third Quarter 2020 Financial Results and Update of Programs
PR
2020DURECT CORPORATION : to Announce Third Quarter 2020 Financial Results and Provide Business..
AQ
2020DURECT CORPORATION : to Participate in the ROTH Capital Partners Healthcare Event 'Covid-1..
AQ
2020DURECT CORPORATION : to Announce Third Quarter 2020 Financial Results and Provide Business..
PR
2020DURECT CORPORATION : to Participate in the ROTH Capital Partners Healthcare Event "Covid-..
PR
2020AVROBIO Appoints Dr. Gail Farfel to its Board of Directors
AQ
2020DURECT CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2020DURECT CORPORATION : to Present Additional Safety and Efficacy Signals from Phase 1b Clini..
PR
2020DURECT CORPORATION : to Participate in Fireside Chat at H.C. Wainwright 4th Annual NASH In..
PR
2020DURECT CORPORATION : Announces First Patient Dosed in Phase 2 Safety and Efficacy Study of..
AQ
2020DURECT CORPORATION : Announces Design of Phase 2b AH Study
AQ
2020DURECT CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
1  2  3  4  5Next
Upcoming event on DURECT CORPORATION